Abstract: The therapeutic use of autologous platelet-rich plasma constitutes a breakthrough in the stimulation and acceleration of soft-tissue healing and bone regeneration. Platelet-rich technologies seek to facilitate anterior cruciate ligament replacement by mimicking the native tissue and improving the adequacy of tissue function with appropriate cues, ultimately leading to better patient care. There are different technical protocols for preparing plateletrich plasma, and the resultant products are typically heterogeneous; moreover, protocols for administrating the products in patients vary extensively. Poor standardization in the field makes full evaluation of different plasma products and establishing standards for the most beneficial applications of this technology difficult. This article presents the current data on the use of plateletrich plasma in the reconstruction of the anterior cruciate ligament. Although the findings are not conclusive, the use of autologous platelet-rich plasma is shown to be safe, reproducible, and effective in mimicking the natural processes of soft tissue and bone healing. Platelet-rich technologies offer new opportunities for research and the application of anterior cruciate ligament tissue engineering.
A torn anterior cruciate ligament (ACL) is a common injury, and is more highly typical among the active young population. It requires surgical intervention to stabilize the knee and prevent cartilage and meniscal injuries, which lead to degenerative joint disease.
1 ACL reconstruction, namely ACL tissue engineering, involves the manipulation of cells and tissues to replace the injured ligament; this process is a complex undertaking, and involves many mechanical and biologic challenges. It requires the application of mechanical knowledge as well as an understanding of how cells maintain and grow into functioning tissues to replace defective or injured ligaments. At present, the most common options in ACL replacement are allografts or autografts. A novel approach using plateletrich (PR) technologies seeks to facilitate ACL healing by mimicking the native tissue and improving the adequacy of tissue function with the appropriate cues, ultimately leading to better patient care.
The therapeutic administration of PR plasma (PRP) extends to the treatment of multiple musculoskeletal disorders and to the regeneration and healing of a wide range of tissues in several medical and scientific fields. 2 In 2003, Sa´nchez et al 3 were the first to report the use of PRP for orthopedic-related problems. Furthermore, they conceived the ''in situ'' preparation of fully integrated bioactive grafts for ACL reconstruction using the now-traditional paradigm of tissue engineering. 4 Since then, PRP and methods for its application (ie, PR therapies) have been further developed, creating new opportunities for tissue repair in sports medicine 5, 6 and even opening the door to novel therapies for the treatment of knee joint pathologies. 7 PRP is an autologous product prepared from the patient's own blood, hence it is safe and biocompatible 7, 8 ; in addition, clearance for marketing (510 k) is achievable without the need for randomized clinical trials and thus the product can be introduced rapidly into the clinical setting. This technology may offer real and clear possibilities of therapeutic application in some of the most important orthopedic problems. In short, the development of this technology could be of outstanding relevance both from social and medical points of view.
The future of ACL reconstruction is based on the fundamental understanding of the relationships among cells, scaffolds, and signaling factors, as this knowledge provides the basis for the development of biologic substitutes to restore, maintain, or improve function in ACL reconstruction. 9 PR therapies contribute to healing by serving as a source of growth factors and cytokines. On the basis of the potential of PR therapies in soft tissue and bone regeneration, we discuss the role of these therapies in enhancing tendon graft ligamentization and the regeneration of bone-bone or tendon-bone interfaces. As one example of an effort to reduce the morbidity associated with autografts, it is possible to introduce PRP to the donor region where the plasma can regenerate tissue. growth factor (TGF-b1), platelet factor 4, vascular endothelial growth factor (VEGF), endostatins, angiopoietins, and thrombospondin-1.
11 PRP releases both angiogenic factors, including VEGF, which has been implicated in the promotion of angiogenesis, and antiangiogenic factors, such as platelet factor 4 and endostatins. The ratio of these factors under local conditions might determine the efficacy of the treatment. 12 Growth factor modulation occurs after the growth factor first binds to a specific cell-surface receptor. This binding triggers the process of signal transduction, during which the occupied receptor initiates a chain of intracellular signaling that results in protein synthesis that then influences tissue healing.
It is well known that tissue healing and remodeling is a complex cascade of biologic events controlled by a large list of cytokines and growth factors that influence various processes such as cell growth, angiogenesis, inflammation, and other mechanisms governing tissue healing and regeneration. Such complexity calls for refined restorative approaches that involve the delivery of multimolecular effective therapies tailored to the exact biologic state of the healing tissues. Autologous PR preparations are already being used as biologic systems for growth factor delivery and tissue engineering. 13 This concept involves enriching the injured site with the patient's own cellular signals, which have the ability to activate local cells as well as to attract precursor cells from the bloodstream, which then take part in the formation of new tissue.
The method of producing PRP determines its composition and concentration in terms of platelets, leukocytes, and erythrocytes in a given plasma volume; this make-up determines the molecules present in a given preparation, the molecular balance, and the concentrations of the respective molecules. There are 2 methods to produce PRP: the single spinning and double spinning procedures. When using the single spinning method, the platelet yield is 1 to 3 times baseline levels, whereas double spinning can yield levels 5 to 8 times baseline levels. Double spinning also concentrates leukocytes; hence, these products are more precisely called leukocyte/platelet concentrates.
14 Whether concentrated leukocytes have a positive or negative influence cannot be generalized for all tissues and clinical conditions, and this point remains a controversial issue that demands further investigation. A priori, we report several concerns regarding the presence of high levels of neutrophils containing MMP-8 (matrix metalloproteinase-8) and MMP-9; MMP-8 is also referred to as neutrophil collagenase and was once thought to be expressed exclusively in neutrophils and polymorphonuclear leukocytes. 15 The release of reactive oxygen species by neutrophils may also be relevant. 16 The successful clinical application of PRP also depends on a clarification of the optimal readministration procedure, the volume of PRP used, and the frequency of the applications. For example, one possible use is for conditioning tendon grafts before implantation by injecting the activated liquid, which results in local fibrin matrix development and in proteins being readily extruded from the matrix in situ (Fig. 1) . Alternatively, the fibrin scaffold can be formed ex vivo, and then implanted into the chosen site before retraction. In addition to providing initial cues for local cell activation and the homing of precursor cells to the injury site for differentiation, platelets and fibrin are also potent adhesive substrates for cells. We used fibrin scaffolds to enhance cicatrization of soft tissues at the donor site.
THE ROLE OF PR THERAPIES IN ACL RECONSTRUCTION
Cell cultures 17, 18 and animal research, [19] [20] [21] [22] in addition to human clinical studies, drive the main hypotheses for the application of PR technology in ACL reconstruction. These applications involve first promoting bone-bone and bonetendon healing and second influencing the pattern of change within the autograft body (ligamentization). Finally, the application of PR therapies will help in donor site healing.
Healing of Bone-bone and Bone-tendon Interfaces
Graft fixation is the weakest link in ACL reconstruction because knee laxity develops during the immediate postoperative period until biologic fixation occurs within the bone tunnel. Classically, graft stabilization is achieved more rapidly with the bone plug-patella tendon-bone (BPTB) grafts than with the hamstring. 23 The BPTB graft becomes anchored to the bone wall via appositional bone formation and, in these circumstances, the use of PRP may aid in the formation of the callus and accelerate bone fusion. Previous animal research and clinical experience showing enhanced bone regeneration in the maxillofacial and dentistry fields support this notion. 24, 25 In orthopedics, Sa´nchez et al 26 evaluated the clinical safety and efficacy of using a particular PRP named PRGF (preparation rich in growth factors) for the treatment of 16 nonhypertrophic nonunions. The mean time from prior surgical treatment was 21 months (9 to 46 mo), and the mean time from surgery and/or PRGF application to union was 4.9 months (2 to 8 mo), with no associated complications. Although the application of PR therapies to enhance BPTB healing is promising, careful evaluation is required to show the true value of PRP application in these circumstances.
Hamstring fixation is considered problematic because it relies on slow tendon-bone incorporation within the tunnels. In normal anatomy, the ACL attaches to the surface of the bone, which contains both uncalcified and calcified fibrocartilage, via direct insertion. However, there are no sites in humans where a tendon goes into a bone tunnel, and therefore, there is no native situation analogous to a tunnel-hamstring graft. Previous approaches aiming to promote bone ingrowth onto a tendon graft placed in a bone tunnel are reviewed elsewhere. 27 Most authors have investigated the influence of synthetic growth factors in the optimization and enhancement of graft-bone interface following common osteoinductive strategies. Rodeo et al 28 used a collagen sponge carrying rhBMP-2 in the grafttunnel in an animal model, whereas Martinek et al 29 used gene therapy techniques. Chen and Anderson 30 attempted more extensive bone formation using periostium wrapped around the tendon graft in the bone tunnel.
At present, there is clinical evidence supporting the beneficial effect of PRP in bone and tendon healing separately, but not in tendon-bone healing, although it should be apparent that autologous growth factors released from PR scaffolds might influence tendon-bone healing at many levels. At a biologic level, healing seems to begin with proliferation of fibrovascular tissue and progress through the maturation of this matrix in the interface between tendon and bone. Typically, PRP application seeks to enhance the initial formation of highly vascular and cellular fibrous tissue that makes up the tendon-bone interface. Ideally, this tissue would mature to a more organized one with continuity of collagen fibers aligned along the direction of the pull of the muscle tendon unit between the tunnel and the graft. Previous research has demonstrated the anabolic effect of PR therapies on tendon cells by stimulating the synthesis of Collagen I, Collagen III and cartilage oligomerix matrix protein, which is believed to have an organizational role in the formation of collagenous matrices. 31, 32 Therefore, the delivery of growth factors should promote collagen hypertrophy and growth factor expression from both the graft and host bone, which may ultimately determine the success of graft integration. Despite the significance of this hypothesis, clinical studies are lacking, as is clear histologic evidence showing Sharpey's fiber development that anchors the tendon to the bone.
In a preliminary study, Sa´nchez et al 4 described a procedure for treating the bone tunnels and conditioning the graft before implantation with PRGF; they compared a group of 50 patients treated with surgery and PRGF with another group of 50 patients who underwent surgery alone. The 2 groups were matched for age and graft type. The authors reported better integration of PRGF-treated grafts within the tunnels, as assessed by x-rays, and a larger number of completely stable knees in the PRGF group. Other authors 33, 34 have explored the influence of autologous bone plugs, either alone or combined with PR therapies, on the promotion of femoral bone-tendon healing. They reported that bone plugs, but not PR therapies, significantly prevented femoral tunnel widening.
We use autologous bone blocks to enhance graft fixation within the tibial tunnel because the tibia is more mechanically demanding 35 than the femur. Our strategy focused on creating biphasic scaffolds made of 2 bone plugs with different sections (11 mm distal and 9 to 10 mm proximal) enrobed in fibrin, as shown in Figure 2 . Typically, when making the tibial tunnel we perform a sequential trephine drilling with escalating diameter sections; initially we start distally with a trephine drill 11 mm wide and 20 mm long and then we change to 9 to 10 mm wide proximally. In doing so, the graft first penetrates a 9 to 10 mm wide tunnel and then expands to 11 mm. Here, the hypothesis states that mechanical strain causes internal deformations within the fibrin matrix affecting the migration and growth of cells that repopulate the fibrin and transform the temporary fibrin into collagen fibers (Fig. 3) . We fix the hamstring at the level of the femoral tunnel with transcondylar screws and, once the graft is placed, activated liquid PRGF is injected into both tunnels to promote intraosseous healing. Figure 4 illustrates intraosseous bone healing 4 months after hamstring implantation was performed using PRGF-assisted protocols.
Ligamentization and Growth Factors
Appropriate function of the ACL graft, essential for normal knee biomechanical functioning, entails successful intra-articular graft ligamentization. Recent research into the remodeling of tissues points to several growth factors that could improve ACL remodeling. Several researchers have focused on examining the effects of the local administration of single growth factors, such as PDGF-BB, 36 TGF-b1, 37, 38 or VEGF
39
; theoretically, all of these factors may stimulate ligamentization. Nevertheless, limiting factors in these studies are related to the requirements for multiple signals to drive the remodeling process to completion, as well as the complex nature of the interdependent factors at play during the period of ligamentization.
One exciting option to enhance ligamentization is to transfer multiple cytokines and growth factors (including PDGF, TGF-b1, and VEGF, among others) to the graft simultaneously, by applying an endogenous PRP. Autografts could be loaded in situ with a balanced pool of signaling molecules. These molecules would have the potential to not only activate the graft tenocytes, 40 but also to attract cells, such as endothelial or stem cells, from adjacent niches (such as the synovium and/or the intrapatellar pad) to graft structures using the synovial fluid for passage. 41 The corroboration and clinical translation of this notion may be enhanced healing and intrasynovial adaptation of the tendon graft to the synovial milieu.
Recently, we have compared the gross appearance and microscopic qualities of the PRGF-treated and PRGFuntreated grafts during the remodeling period (6-24 mo). Gross morphology was evaluated on second-look arthroscopy focusing on graft thickness, apparent tension, and synovium coverage. The overall arthroscopic evaluation evidenced a higher percentage rated as excellent in the PRGF group (57% vs. 33%). No grafts were scored as poor in the PRGF group, but 20% of the controls showed poor morphology. At the same time, PRGF treatment influenced the histologic characteristics of the tendon graft, resulting in tissue that was more mature than in the controls. Histology displayed newly formed connective tissue enveloping the graft in 77.3% of PRGF-treated grafts and in 40% of controls. 42 On the basis of histologic findings, we suggest that the remodeling of PRGF-treated grafts involves the formation of synovial-like tissue enveloping the graft, eventually integrated in the remodeled tendon graft and conferring a similar appearance to the ACL (Fig. 2) . Radice 43 and Orrego et al 33 independently confirmed the acceleration of the maturation of grafts treated with PRP, using a rating magnetic resonance imaging score to evaluate graft homogeneity. In these studies, the PRP product and the procedure for its application vary from the Sa´nchez approach. Radice 42 and Orrego et al 33 used a compressed gelatin sponge soaked with leukocyte and PR concentrate (GPS system by Biomet Biologic, Warsaw), which is then sutured to the intra-articular part of the graft.
Donor Site Repair
Autografts are associated with donor site morbidity in up to 40% of all patients. 44 In light of the high donor site morbidity, allografts have come into increasing use. A recent meta-analysis comparing allograft and autograft stability showed that allograft ACL reconstruction produced significantly lower levels of stability than that with autografts. 45 If it is possible to reduce donor site morbidity, autografts rather than allografts may offer greater advantages. Studies have confirmed that local application of PR preparations is especially important in conditions where healing is compromised due to tissue discontinuity. In fact, the dynamic and efficient process of wound healing involves a complex series of events including hemostasis, inflammation, granulation tissue formation, epithelialization, neovascularization, collagen synthesis, and wound contraction. Blood platelets have a major role in the initiation of wound healing. They adhere, aggregate, and release numerous growth factors, adhesive molecules, and lipids that regulate the migration, proliferation, and function of fibroblasts and endothelial cells. Preclinical and clinical studies with PRGF have shown that it can accelerate tissue repair in soft tissues via mechanisms involving the further synthesis of signaling proteins that participate in cell mitosis and angiogenesis. 46, 47 Another important consideration is that in addition to stimulating the growth of new tissue, PRP application decreased pain and inflammation. [48] [49] [50] 
CONCLUSIONS
The delivery of endogenous signaling molecules during ACL surgery may result in significant changes in the biologic function of the local cells. However, the production of tissue that is biologically, chemically, and mechanically normal will require a combination of strategies. Thus, combining the use of PR products with appropriate mechanical loading methods might yield both better tissue organization in the short term and enhanced mechanical properties in the long term, both of which are of paramount importance in young active patients. PR preparations are one of many in the novel biologic armamentarium of therapies as they promote the healing of tissue with a range of endogenous cell signaling factors. They provide a potential advantage for better and more predictable ligamentization and enhanced tendon-bone healing, suggesting an exciting role for PR therapies in ACL surgery. However, poor standardization in the field has hampered the evaluations of different plasma products and the establishment of standard beneficial application of this technology.
